Is BHC or LNTH more profitable?

Lantheus has a net margin of 18.05% compared to Bausch Health Cos' net margin of -11.47%. Lantheus' return on equity of 29.32% beat Bausch Health Cos' return on equity. Company Net Margins Return on Equity Return on Assets Bausch Health Cos -11.47% -2,922.77% 5.63% Lantheus 18.05% 29.32% 15.00%

Does the media prefer BHC or LNTH?

In the previous week, Bausch Health Cos and Bausch Health Cos both had 4 articles in the media. Lantheus' average media sentiment score of 1.19 beat Bausch Health Cos' score of -0.32 indicating that Lantheus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bausch Health Cos 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Lantheus 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BHC or PTCT?

In the previous week, PTC Therapeutics had 8 more articles in the media than Bausch Health Cos. MarketBeat recorded 12 mentions for PTC Therapeutics and 4 mentions for Bausch Health Cos. PTC Therapeutics' average media sentiment score of 0.57 beat Bausch Health Cos' score of -0.32 indicating that PTC Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bausch Health Cos 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral PTC Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to COGT or BHC?

In the previous week, Bausch Health Cos had 1 more articles in the media than Cogent Biosciences. MarketBeat recorded 4 mentions for Bausch Health Cos and 3 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 1.60 beat Bausch Health Cos' score of -0.32 indicating that Cogent Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Bausch Health Cos 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to SRRK or BHC?

In the previous week, Scholar Rock had 10 more articles in the media than Bausch Health Cos. MarketBeat recorded 14 mentions for Scholar Rock and 4 mentions for Bausch Health Cos. Scholar Rock's average media sentiment score of -0.10 beat Bausch Health Cos' score of -0.32 indicating that Scholar Rock is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scholar Rock 3 Very Positive mention(s) 5 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bausch Health Cos 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Bausch Health Cos (BHC) Competitors

$4.78 -0.01 (-0.10%)

Closing price 07/10/2026 03:59 PM Eastern

Extended Trading

$4.78 0.00 (0.00%)

As of 04:00 AM Eastern

Compare

BHC vs. LNTH, PTCT, COGT, SRRK, and CNTA

Should you buy Bausch Health Cos stock or one of its competitors? MarketBeat compares Bausch Health Cos with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bausch Health Cos include Lantheus (LNTH), PTC Therapeutics (PTCT), Cogent Biosciences (COGT), Scholar Rock (SRRK), and Centessa Pharmaceuticals (CNTA). These companies are all part of the "pharmaceutical products" industry.

How does Bausch Health Cos compare to Lantheus?

Bausch Health Cos (NYSE:BHC) and Lantheus (NASDAQ:LNTH) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation, dividends and media sentiment.

Bausch Health Cos currently has a consensus target price of $8.00, indicating a potential upside of 67.54%. Lantheus has a consensus target price of $108.29, indicating a potential upside of 2.50%. Given Bausch Health Cos' higher possible upside, research analysts clearly believe Bausch Health Cos is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch Health Cos	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

Lantheus has a net margin of 18.05% compared to Bausch Health Cos' net margin of -11.47%. Lantheus' return on equity of 29.32% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch Health Cos	-11.47%	-2,922.77%	5.63%
Lantheus	18.05%	29.32%	15.00%

78.7% of Bausch Health Cos shares are owned by institutional investors. Comparatively, 99.1% of Lantheus shares are owned by institutional investors. 20.7% of Bausch Health Cos shares are owned by company insiders. Comparatively, 1.7% of Lantheus shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Lantheus has lower revenue, but higher earnings than Bausch Health Cos. Bausch Health Cos is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch Health Cos	$10.27B	0.17	$157M	-$3.24	N/A
Lantheus	$1.54B	4.46	$233.56M	$4.15	25.46

In the previous week, Bausch Health Cos and Bausch Health Cos both had 4 articles in the media. Lantheus' average media sentiment score of 1.19 beat Bausch Health Cos' score of -0.32 indicating that Lantheus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bausch Health Cos	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Lantheus	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bausch Health Cos has a beta of 0.42, indicating that its share price is 58% less volatile than the broader market. Comparatively, Lantheus has a beta of -0.06, indicating that its share price is 106% less volatile than the broader market.

Summary

Lantheus beats Bausch Health Cos on 11 of the 15 factors compared between the two stocks.

How does Bausch Health Cos compare to PTC Therapeutics?

Bausch Health Cos (NYSE:BHC) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.

78.7% of Bausch Health Cos shares are owned by institutional investors. 20.7% of Bausch Health Cos shares are owned by insiders. Comparatively, 5.5% of PTC Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Bausch Health Cos presently has a consensus price target of $8.00, indicating a potential upside of 67.54%. PTC Therapeutics has a consensus price target of $91.57, indicating a potential upside of 7.92%. Given Bausch Health Cos' higher probable upside, research analysts clearly believe Bausch Health Cos is more favorable than PTC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch Health Cos	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
PTC Therapeutics	2 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.80

Bausch Health Cos has a net margin of -11.47% compared to PTC Therapeutics' net margin of -22.58%. PTC Therapeutics' return on equity of -362.45% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch Health Cos	-11.47%	-2,922.77%	5.63%
PTC Therapeutics	-22.58%	-362.45%	-6.76%

PTC Therapeutics has lower revenue, but higher earnings than Bausch Health Cos. PTC Therapeutics is trading at a lower price-to-earnings ratio than Bausch Health Cos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch Health Cos	$10.27B	0.17	$157M	-$3.24	N/A
PTC Therapeutics	$1.73B	4.07	$682.64M	-$2.33	N/A

Bausch Health Cos has a beta of 0.42, suggesting that its stock price is 58% less volatile than the broader market. Comparatively, PTC Therapeutics has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market.

In the previous week, PTC Therapeutics had 8 more articles in the media than Bausch Health Cos. MarketBeat recorded 12 mentions for PTC Therapeutics and 4 mentions for Bausch Health Cos. PTC Therapeutics' average media sentiment score of 0.57 beat Bausch Health Cos' score of -0.32 indicating that PTC Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bausch Health Cos	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
PTC Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

PTC Therapeutics beats Bausch Health Cos on 10 of the 17 factors compared between the two stocks.

How does Bausch Health Cos compare to Cogent Biosciences?

Cogent Biosciences (NASDAQ:COGT) and Bausch Health Cos (NYSE:BHC) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings, media sentiment and analyst recommendations.

78.7% of Bausch Health Cos shares are owned by institutional investors. 6.6% of Cogent Biosciences shares are owned by company insiders. Comparatively, 20.7% of Bausch Health Cos shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Cogent Biosciences has a beta of 0.34, indicating that its stock price is 66% less volatile than the broader market. Comparatively, Bausch Health Cos has a beta of 0.42, indicating that its stock price is 58% less volatile than the broader market.

Cogent Biosciences has a net margin of 0.00% compared to Bausch Health Cos' net margin of -11.47%. Cogent Biosciences' return on equity of -104.27% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-104.27%	-54.64%
Bausch Health Cos	-11.47%	-2,922.77%	5.63%

Bausch Health Cos has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than Bausch Health Cos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A
Bausch Health Cos	$10.27B	0.17	$157M	-$3.24	N/A

Cogent Biosciences currently has a consensus price target of $43.73, suggesting a potential upside of 12.50%. Bausch Health Cos has a consensus price target of $8.00, suggesting a potential upside of 67.54%. Given Bausch Health Cos' higher probable upside, analysts clearly believe Bausch Health Cos is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
Bausch Health Cos	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

In the previous week, Bausch Health Cos had 1 more articles in the media than Cogent Biosciences. MarketBeat recorded 4 mentions for Bausch Health Cos and 3 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 1.60 beat Bausch Health Cos' score of -0.32 indicating that Cogent Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Bausch Health Cos	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Bausch Health Cos beats Cogent Biosciences on 9 of the 16 factors compared between the two stocks.

How does Bausch Health Cos compare to Scholar Rock?

Scholar Rock (NASDAQ:SRRK) and Bausch Health Cos (NYSE:BHC) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, valuation, earnings, dividends, analyst recommendations and risk.

Scholar Rock has a net margin of 0.00% compared to Bausch Health Cos' net margin of -11.47%. Scholar Rock's return on equity of -163.52% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-163.52%	-96.67%
Bausch Health Cos	-11.47%	-2,922.77%	5.63%

Scholar Rock currently has a consensus target price of $56.00, suggesting a potential downside of 1.25%. Bausch Health Cos has a consensus target price of $8.00, suggesting a potential upside of 67.54%. Given Bausch Health Cos' higher possible upside, analysts clearly believe Bausch Health Cos is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12
Bausch Health Cos	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

91.1% of Scholar Rock shares are owned by institutional investors. Comparatively, 78.7% of Bausch Health Cos shares are owned by institutional investors. 10.3% of Scholar Rock shares are owned by insiders. Comparatively, 20.7% of Bausch Health Cos shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Scholar Rock has a beta of 0.67, indicating that its stock price is 33% less volatile than the broader market. Comparatively, Bausch Health Cos has a beta of 0.42, indicating that its stock price is 58% less volatile than the broader market.

In the previous week, Scholar Rock had 10 more articles in the media than Bausch Health Cos. MarketBeat recorded 14 mentions for Scholar Rock and 4 mentions for Bausch Health Cos. Scholar Rock's average media sentiment score of -0.10 beat Bausch Health Cos' score of -0.32 indicating that Scholar Rock is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	3 Very Positive mention(s)	5 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bausch Health Cos	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Bausch Health Cos has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Bausch Health Cos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A
Bausch Health Cos	$10.27B	0.17	$157M	-$3.24	N/A

Summary

Scholar Rock beats Bausch Health Cos on 9 of the 16 factors compared between the two stocks.

How does Bausch Health Cos compare to Centessa Pharmaceuticals?

Centessa Pharmaceuticals (NASDAQ:CNTA) and Bausch Health Cos (NYSE:BHC) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

Centessa Pharmaceuticals has a beta of 1.11, suggesting that its stock price is 11% more volatile than the broader market. Comparatively, Bausch Health Cos has a beta of 0.42, suggesting that its stock price is 58% less volatile than the broader market.

Centessa Pharmaceuticals presently has a consensus price target of $41.33, suggesting a potential upside of 2.06%. Bausch Health Cos has a consensus price target of $8.00, suggesting a potential upside of 67.54%. Given Bausch Health Cos' higher possible upside, analysts clearly believe Bausch Health Cos is more favorable than Centessa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Bausch Health Cos	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Bausch Health Cos has higher revenue and earnings than Centessa Pharmaceuticals. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Bausch Health Cos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Centessa Pharmaceuticals	N/A	N/A	-$197.53M	-$1.79	N/A
Bausch Health Cos	$10.27B	0.17	$157M	-$3.24	N/A

Centessa Pharmaceuticals has a net margin of 0.00% compared to Bausch Health Cos' net margin of -11.47%. Centessa Pharmaceuticals' return on equity of -60.37% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%
Bausch Health Cos	-11.47%	-2,922.77%	5.63%

82.0% of Centessa Pharmaceuticals shares are held by institutional investors. Comparatively, 78.7% of Bausch Health Cos shares are held by institutional investors. 4.1% of Centessa Pharmaceuticals shares are held by insiders. Comparatively, 20.7% of Bausch Health Cos shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Bausch Health Cos had 4 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 4 mentions for Bausch Health Cos and 0 mentions for Centessa Pharmaceuticals. Centessa Pharmaceuticals' average media sentiment score of 0.00 beat Bausch Health Cos' score of -0.32 indicating that Centessa Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Centessa Pharmaceuticals	Neutral
Bausch Health Cos	Neutral

Summary

Centessa Pharmaceuticals beats Bausch Health Cos on 8 of the 15 factors compared between the two stocks.

Get Bausch Health Cos News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BHC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BHC vs. The Competition

Export

Metric	Bausch Health Cos	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$1.79B	$6.07B	$6.89B	$23.43B
Dividend Yield	N/A	0.66%	2.68%	4.02%
P/E Ratio	-1.47	8.39	27.33	31.40
Price / Sales	0.17	29.49	510.94	170.55
Price / Cash	0.66	8.46	29.24	18.64
Price / Book	4.68	4.32	10.98	4.77
Net Income	$157M	$99.67M	$3.59B	$1.06B
7 Day Performance	-0.83%	-1.78%	-0.92%	-0.39%
1 Month Performance	-5.54%	9.15%	4.57%	0.05%
1 Year Performance	-25.74%	121.65%	29.78%	17.05%

Bausch Health Cos Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BHC Bausch Health Cos	2.5093 of 5 stars	$4.78 -0.1%	$8.00 +67.5%	-25.7%	$1.79B	$10.27B	N/A	20,300
LNTH Lantheus	3.0904 of 5 stars	$102.82 -6.4%	$101.86 -0.9%	+29.9%	$7.15B	$1.54B	24.78	1,193
PTCT PTC Therapeutics	2.6629 of 5 stars	$85.44 +2.6%	$91.36 +6.9%	+74.8%	$6.91B	$1.73B	N/A	1,410
COGT Cogent Biosciences	1.8675 of 5 stars	$39.44 +1.9%	$43.73 +10.9%	+254.0%	$6.61B	N/A	N/A	80	Positive News Gap Up
SRRK Scholar Rock	1.4726 of 5 stars	$55.36 +0.9%	$56.00 +1.2%	+51.5%	$6.58B	N/A	N/A	140

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:BHC) was last updated on 7/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bausch Health Cos (BHC) Competitors

BHC vs. LNTH, PTCT, COGT, SRRK, and CNTA

How does Bausch Health Cos compare to Lantheus?

Summary

How does Bausch Health Cos compare to PTC Therapeutics?

Summary

How does Bausch Health Cos compare to Cogent Biosciences?

Summary

How does Bausch Health Cos compare to Scholar Rock?

Summary

How does Bausch Health Cos compare to Centessa Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BHC vs. The Competition

Bausch Health Cos Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bausch Health Cos (BHC) Competitors

BHC vs. LNTH, PTCT, COGT, SRRK, and CNTA

How does Bausch Health Cos compare to Lantheus?

Do analysts rate BHC or LNTH?

Is BHC or LNTH more profitable?

Do insiders and institutionals believe in BHC or LNTH?

Which has preferable earnings & valuation, BHC or LNTH?

Does the media prefer BHC or LNTH?

Which has more risk & volatility, BHC or LNTH?

Summary

How does Bausch Health Cos compare to PTC Therapeutics?

Do institutionals & insiders believe in BHC or PTCT?

Do analysts prefer BHC or PTCT?

Is BHC or PTCT more profitable?

Which has preferable valuation and earnings, BHC or PTCT?

Which has more risk & volatility, BHC or PTCT?

Does the media prefer BHC or PTCT?

Summary

How does Bausch Health Cos compare to Cogent Biosciences?

Do institutionals and insiders hold more shares of COGT or BHC?

Which has more risk and volatility, COGT or BHC?

Is COGT or BHC more profitable?

Which has higher valuation and earnings, COGT or BHC?

Do analysts prefer COGT or BHC?

Does the media refer more to COGT or BHC?

Summary

How does Bausch Health Cos compare to Scholar Rock?

Is SRRK or BHC more profitable?

Do analysts prefer SRRK or BHC?

Do institutionals & insiders hold more shares of SRRK or BHC?

Which has more volatility and risk, SRRK or BHC?

Does the media refer more to SRRK or BHC?

Which has stronger earnings & valuation, SRRK or BHC?

Summary

How does Bausch Health Cos compare to Centessa Pharmaceuticals?

Which has more volatility & risk, CNTA or BHC?

Do analysts prefer CNTA or BHC?

Which has preferable valuation & earnings, CNTA or BHC?

Is CNTA or BHC more profitable?

Do institutionals and insiders hold more shares of CNTA or BHC?

Does the media favor CNTA or BHC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BHC vs. The Competition

Bausch Health Cos Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools